Battle Over Deferred Drug Listings In Australia: Should Cost-Effective Drugs Always Be Funded?
This article was originally published in PharmAsia News
A storm is brewing in the lead up to Australia's May 10 federal budget over the nation's Pharmaceutical Benefits Scheme, which acts as a single payer to subsidize drug prices and is administered by the government
You may also be interested in...
As Global Payers Become Monopolies, Biopharma Need To Demonstrate Value Earlier – AusBiotech Conference
Biopharma companies should define value propositions early and have a case for value differentiation at the discovery stage if they want to make a case to payers.
A new government in Australia faces a budget gap that will soon bring health care reimbursement with industry focused on a pledge by the Liberal Party to restore the independence of the Pharmaceutical Benefits Advisory Committee.
Australia’s Federal Election is on Sept. 7, and both Medicines Australia and AusBiotech have been lobbying the Labor and the Liberal National parties to see what the incoming government can offer the pharmaceutical, medical device and biotechnology industries.